Roche Reveals Results from the P-I Clinical Evaluation of CT-388 for Treating Obesity and Type 2 Diabetes
Shots:
- The P-I (CT-388-101) study assesses the safety, tolerability & PK/PD of CT-388 (QW, SC) vs PBO to treat otherwise healthy adults with obesity and individuals with both obesity & type-2 diabetes mellitus
- The study showed a significant weight loss in healthy obese adults with a mean PBO-adjusted weight loss of 18.8%. The weight loss observed at wk.24 by 100% of subjects was >5% with 85% attaining >10%, 70% attaining >15% & 45% attaining >20%. All pre-diabetic individuals at baseline became normoglycemic post 24wks. with the PBO group remaining unchanged
- Furthermore, the company will assess T2D obese patients (BMI>30 kg/m^2) in an additional arm for 12wks. with the results anticipated in H2’24
Ref: Roche | Image: Roche
Related News:- Roche Receives the US FDA’s Approval for HPV Self-Collection Solutions for Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
